Search hospitals > Michigan > Ann Arbor

University of Michigan

Claim this profile
Ann Arbor, Michigan 48109
Global Leader in Fibrosing Colonopathy
Global Leader in Lymphoma
Conducts research for Cancer
Conducts research for Breast Cancer
Conducts research for Post-Implantation Syndrome
1923 reported clinical trials
266 medical researchers
Photo of University of Michigan in Ann ArborPhoto of University of Michigan in Ann Arbor

Summary

University of Michigan is a medical facility located in Ann Arbor, Michigan. This center is recognized for care of Fibrosing Colonopathy, Lymphoma, Cancer, Breast Cancer, Post-Implantation Syndrome and other specialties. University of Michigan is involved with conducting 1,923 clinical trials across 2,202 conditions. There are 266 research doctors associated with this hospital, such as Rajen Mody, MD, MS, Elie G. Dib, Paul Swiecicki, and Rashmi Chugh, MD.

Area of expertise

1Fibrosing Colonopathy
Global Leader
University of Michigan has run 99 trials for Fibrosing Colonopathy. Some of their research focus areas include:
CFTR positive
CFTR
rs3570920 TT positive
2Lymphoma
Global Leader
University of Michigan has run 96 trials for Lymphoma. Some of their research focus areas include:
Stage IV
Stage III
ARID1A positive

Top PIs

Clinical Trials running at University of Michigan

Multiple Myeloma
Ovarian Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Breast Cancer
Heart Failure
Myelofibrosis
Plasma Cell Neoplasm
Pre-eclampsia
Image of trial facility.

Elranatamab vs Lenalidomide

for Multiple Myeloma

The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years
Recruiting2 awards Phase 38 criteria
Image of trial facility.

Anitocabtagene Autoleucel

for Multiple Myeloma

The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM.
Recruiting2 awards Phase 33 criteria
Image of trial facility.

Mezigdomide Combo vs. Pomalidomide Combo

for Multiple Myeloma

This trial is testing two drug combinations to find out which one is better and safer for patients with multiple myeloma that has come back or not responded to previous treatments. The drugs work together to kill cancer cells by stopping their growth, helping the immune system attack them, and making it harder for them to survive.
Recruiting2 awards Phase 3

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Michigan?
Where is University of Michigan located?
Who should I call to ask about financial aid or insurance network?
What insurance does University of Michigan accept?
What awards or recognition has University of Michigan received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security